Headlines
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Published by Global Banking and Finance Review
Posted on October 15, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on October 15, 2025
(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday.
As part of the agreement, Novo gains exclusive global rights to develop and commercialize Omeros' drug zaltenibart, designed to inhibit MASP-3 — a protein that acts as a key activator of the alternative pathway of complement.
The complement pathway is a system of proteins in the blood that enhances the immune system's ability to fight infections.
Omeros is eligible to receive up to a total of $2.1 billion, including $340 million upfront and near-term milestone payments.
The company had said in March it began enrollment for late-stage trials studying the drug for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which part of the immune system attacks and damages the red blood cells and platelets.
Zaltenibart has shown several potential advantages over other alternative pathway inhibitors currently in development or on the market, the companies said.
The drug was safe and well tolerated in the trials.
After the deal closes, expected in the fourth quarter of 2025, Novo aims to start a global program for zaltenibart in PNH and explore development in a range of other rare blood and kidney disorders.
Omeros remains focused on securing approval for its other experimental drug, narsoplimab, this quarter.
The company is pursuing approval for narsoplimab in the U.S. and in Europe to treat transplant-associated thrombotic microangiopathy, a complication that can arise after hematopoietic cell transplantation.
Omeros also retains certain rights to its preclinical MASP-3 programs unrelated to zaltenibart, including the ability to develop and commercialize small-molecule MASP-3 inhibitors with limited indication restrictions.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)